Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
ITCIIntra-Cellular Therapies(ITCI) ZACKS·2024-08-07 21:46

Intra-Cellular Therapies (ITCI) came out with a quarterly loss of 0.16pershareversustheZacksConsensusEstimateofalossof0.16 per share versus the Zacks Consensus Estimate of a loss of 0.18. This compares to loss of 0.45pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof11.110.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of 0.31 per share when it actually produced a loss of $0.16, delivering a surprise of 48.39%.Over the last four quarter ...